空间限域IL-12通过mTORC1编程CAR-NK协调抗肿瘤免疫网络
实体瘤因免疫抑制微环境限制免疫细胞持久性与功能而逃避治疗。研究者构建整合IL-12信号的CAR-NK平台,IL-12与CAR激活协同经Ras-ERK与PI3K通路维持mTORC1活性,促进代谢适应、自主扩增与持续效应功能,并激活旁观NK细胞、T细胞与巨噬细胞重塑微环境。将IL-12锚定于胶原结合A3结构域限制于细胞外基质以减少全身暴露,在卵巢癌与胰腺癌模型中实现无需外源细胞因子的扩增与持久肿瘤控制。
要点
- IL-12信号与CAR激活协同经Ras-ERK和PI3K通路维持mTORC1活性。
- 基质锚定IL-12限制全身暴露,在卵巢癌与胰腺癌模型中实现持久肿瘤控制。
- IL-12可激活旁观NK细胞、T细胞与巨噬细胞以重塑肿瘤微环境。
核心结论
- mTORC1介导的CAR与细胞因子信号整合可增强免疫适应度并克服免疫抑制性肿瘤微环境。
研究设计与样本
- 工程化整合IL-12信号的CAR自然杀伤(NK)细胞平台研究,并在卵巢癌与胰腺癌模型中进行验证。
主要发现
- IL-12信号与CAR激活协同经汇聚的Ras-ERK和PI3K通路维持mTORC1活性,促进代谢适应、自主扩增和持续效应功能。
- IL-12激活旁观NK细胞、T细胞和巨噬细胞以重塑肿瘤微环境。
- 基质锚定IL-12的CAR-NK细胞在卵巢癌与胰腺癌模型中无需外源细胞因子即可扩增并实现持久肿瘤控制。
关键数值与推荐
- IL-12通过胶原结合A3结构域锚定于细胞外基质,限制其活性并减少全身暴露。
临床怎么用
- 该策略提示可将细胞因子信号空间限域于肿瘤基质以降低全身毒性并增强CAR-NK在实体瘤中的持久性与疗效。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Solid tumors evade immunotherapy because of immunosuppressive microenvironments that limit immune cell persistence and function. Although interleukin-12 (IL-12) potently activates antitumor immunity, its clinical use has been constrained by systemic toxicity. Here we engineered a CAR natural killer (NK) cell platform that integrated IL-12 signaling to enhance antitumor immunity. IL-12 signaling synergized with CAR activation to sustain mTORC1 activity through convergent Ras-ERK and PI3K pathways, promoting metabolic fitness, autonomous expansion, and sustained effector function. IL-12 also activated bystander NK cells, T cells, and macrophages to remodel the tumor microenvironment. To improve safety, IL-12 was tethered to a collagen-binding A3-domain, restricting its activity to the extracellular matrix and limiting systemic exposure. In ovarian and pancreatic cancer models, matrix-anchored IL-12 CAR NK cells expanded without exogenous cytokines and achieved durable tumor control. These findings suggest that mTORC1-mediated integration of CAR and cytokine signaling can enhance immune fitness and overcome immunosuppressive tumor microenvironments.
引用
- Tarannum M, Dinh K, Stanojevic M, et al. Spatially confined IL-12 programs CAR-NK through mTORC1 to coordinate antitumor immune networks. Cancer Discov. 2026. PMID: 42810409. doi:10.1158/2159-8290.CD-26-0509
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。